Neuronetics, Inc. (STIM) reported Q3 Fiscal 2025 results characterized by high growth offset by severe margin compression following the December 2024 acquisition of Greenbrook TMS.
Financial Performance & Margins: Revenue nearly doubled year-over-year for both the quarter (\(37.3M, up 101%) and the nine months ended Sept. 30, 2025 (\)107.4M vs. \(52.4M in 2024). However, Gross Margin collapsed from 75.6% to 45.9% because Clinic Revenue now comprises 60% of the US sales mix. The 9-month Net Loss slightly widened to (\)31.9M) from (\(31.0M), though the Q3 Net Loss narrowed to (\)9.4M). The Accumu
...